False-negative scintigraphy with Tc-99m sestamibi in stage IV neuroblastoma


OZCAN Z. , ERENEL G., AKSOYLAR S. , KANSOY S. , Burak Z. , OZKILIC H.

CLINICAL NUCLEAR MEDICINE, cilt.24, ss.267-270, 1999 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 24 Konu: 4
  • Basım Tarihi: 1999
  • Doi Numarası: 10.1097/00003072-199904000-00011
  • Dergi Adı: CLINICAL NUCLEAR MEDICINE
  • Sayfa Sayıları: ss.267-270

Özet

Tc-99m sestamibi, originally developed for myocardial studies, has been used as a tumor-seeking agent. Recently, the agent also was reported to be a functional tracer to predict multidrug resistance-related p-glycoprotein expression in tumor tissue. The current report presents the authors' experience with sestamibi tumor scintigraphy in a neuroblastoma. Although I-131 MIBG tumor imaging and Tc-99m MDP bone scanning accurately demonstrated the extent of the disease, Tc-99m sestamibi showed no accumulation in primary and metastatic foci. Lack of sestamibi uptake was initially thought to be suggestive of failure to respond to chemotherapy because of p-glycoprotein expression. However, the patient responded well to chemotherapy and complete remission was achieved. The failure of Tc-99m sestamibi to detect a neuroblastoma and the lack of sestamibi accumulation in the tumor may not always be related to chemotherapy resistance.